The effect of Pilocarpine on absorbed salivary gland dose in patients on radioiodine therapy.

Phase 2

• Conditions: Thyroid Cancer therapy with I-131.; Malignant neoplasms of thyroid and other endocrine glands; C73-C75

• Registration Number: IRCT2014060917684N3
• Lead Sponsor: Shiraz university of medical science, Vice chancellor for research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients with diagnosis of hyperthyroidism or thyroid cancer who are candidate for radioiodine therapy
Exclusion criteria: patient with history of uncontrolled asthma; bronchospasm; severe COPD; heart failure; acute iritis; close angle glaucoma; pateint use antihypertensive drugs; history of salivary gland disease; no patient consent.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Organ dose per administered I131 Activity (ODPA). Timepoint: 1,2,3,4,5,13,25,48 h after receiving radio-iodine 131. Method of measurement: By scintigraphy and MIRD Schema software calculations.

Secondary Outcome Measures

Name	Time	Method
Side effects of radio-Iodine 131. Timepoint: Every 4-6 weeks. Method of measurement: Asking the patient.